CN108218998A - A kind of Fc segments of saltant type humanized IgG and preparation method and application - Google Patents
A kind of Fc segments of saltant type humanized IgG and preparation method and application Download PDFInfo
- Publication number
- CN108218998A CN108218998A CN201711496466.5A CN201711496466A CN108218998A CN 108218998 A CN108218998 A CN 108218998A CN 201711496466 A CN201711496466 A CN 201711496466A CN 108218998 A CN108218998 A CN 108218998A
- Authority
- CN
- China
- Prior art keywords
- segments
- humanized igg
- saltant type
- type humanized
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 108091006020 Fc-tagged proteins Proteins 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 3
- YXXURDJTDAAEPH-UHFFFAOYSA-N 2-aminopropanethioic s-acid Chemical compound CC(N)C(S)=O YXXURDJTDAAEPH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 230000002776 aggregation Effects 0.000 abstract description 19
- 238000004220 aggregation Methods 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102000009490 IgG Receptors Human genes 0.000 description 6
- 108010073807 IgG Receptors Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 1
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- KNNSUUOHFVVJOP-GUBZILKMSA-N His-Glu-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N KNNSUUOHFVVJOP-GUBZILKMSA-N 0.000 description 1
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 1
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- -1 therefore compare Fc Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a kind of Fc segments of saltant type humanized IgG and preparation method and application.In CH2 the and CH3 structural domains of Fc segments a pair of of disulfide bond is introduced respectively, and then put forward high molecular stability and resistant to aggregation ability.For the Fc segments of saltant type humanized IgG relative to the Fc of wild type, stability is more preferable, can reduce the production of monoclonal antibody or Fc fusion proteins, purifying, preserve cost；Its resistant to aggregation ability is more preferable, and can reduce leads to Clinical practice risk because of the aggregation of albumen.
Description
Technical field
The present invention relates to biotechnology, in particular to a kind of Fc segments of saltant type humanized IgG and preparation method thereof
With application.
Background technology
Antibody is widely used in every field, especially life science and clinic with its high specificity, high sensitivity
It treats such as ELISA, Western blot, immunofluorescence analysis, disease quick diagnosis and biological agent is used as to treat various diseases
Disease.Therefore, since the 21th century, people also begin to increasingly pay close attention to the research and development and clinical practice of therapeutic antibodies drug, this
It is because it is small to human body toxic side effect, has the effect of natural and high degree of specificity, and has createed huge society's effect
Benefit and economic benefit.
Meanwhile the fusion protein based on Fc segments not only with its molecular weight it is relatively small and with good tissue infiltration
Property, and the Fc segments being coupled thus can extend the blood plasma half of drug with the effects interaction of molecules such as Fc receptors (FcRn)
Decline phase and inducible ADCC, CDC effect or phagocytosis.
However, these antibody drugs and Fc fusion proteins, as bioactive macromolecule, it also has the limitation of itself,
If stability is poor, resistant to aggregation ability is weak, during its expression, purifying, storage etc., can tend to assemble or degrade.And egg
Immunogenicity caused by white aggregation, not only reduces drug effect, while very big risk is also brought to clinical practice.Therefore, it carries
Highly resistance body heat stability and resistant to aggregation ability are one of the field urgent problems to be solved.
Invention content
It is an object of the invention to overcome the defects of Fc segments stability is poor, resistant to aggregation ability is weak in the prior art, provide
A kind of Fc segments of saltant type humanized IgG and preparation method and application, compared with wild type Fc, stability and resistant to aggregation energy
Power is improved, and is of great significance in the research and development, production, clinical practice of antibody or Fc fusion proteins.
To achieve the above object, it is by Ren Yuan the present invention provides a kind of Fc segments of the saltant type humanized IgG
It is obtained after introducing disulfide bond in the CH2 structural domains of the Fc segments of IgG and CH3 structural domains.
In said program preferably, the 242nd in the amino acid sequence of the Fc segments of the saltant type humanized IgG the, the 334th
Position, the 343rd and the 431st amino acid for cysteine, (amino acid position number is referring to http://www.imgt.org/
Eu numbering in IMGTScientificChart/Numbering/Hu_IGHG nber.html, the same below).
Preferably, the Fc segments of the saltant type humanized IgG, are named as S23, and amino acid full length sequence is Seq ID
No.1。
Optionally, the coding gene sequence of the Fc segments of the saltant type humanized IgG is Seq ID No.2.
The present invention also provides the preparation methods of the Fc segments of above-mentioned saltant type humanized IgG, and its step are as follows：
(1) gene of the Fc segments of humanized IgG is obtained；
(2) design primer amplifies to obtain by the designated amino acid base mutation in Fc into the base of encoding aminothiopropionic acid
Saltant type Fc；
(3) carrier for expression of eukaryon being built with saltant type Fc gene orders, transfection mammalian cell carries out eukaryotic expression,
Purifying obtains target Fc segments.
Present invention further teaches above-mentioned saltant type humanized IgG application of the Fc segments in Fc fusion proteins are prepared and
Prepare the application in monoclonal antibody.
The present invention by the methods of CD, molecular sieve, fluorescence detector, ultraviolet specrophotometer, ELISA to the two level of S23
Structure, existence form, stability, resistance to aggregation are identified, are compareed with wild type Fc.Related experiment also turns out S23
It can be combined with Fc receptors, therefore, modify while improved S23 improves itself physicochemical property and do not destroy itself
Biological effect.
Beneficial effects of the present invention：
1) relative to the Fc of wild type, stability is more preferable, can reduce monoclonal antibody or Fc fusion proteins production,
Purifying preserves cost；
2) relative to the Fc of wild type, resistant to aggregation ability is more preferable, and can reduce causes clinic to make because of the aggregation of albumen
Use risk.
Description of the drawings
Fig. 1 is protein immunoblot detection figure after the expression and purification of Fc, S23 albumen.
Fig. 2 is SDS electrophoretograms after the expression and purification of Fc, S23 albumen.
Fig. 3 is the existence form analysis chart (monomer, dimer etc.) of Fc, S23 protein molecular.
Fig. 4 is the analysis chart of C.D analysis Fc, S23 molecular conformation.
Fig. 5 compares figure for stability of Fc, S23 albumen under denaturant conditions.
Fig. 6 compares figure for Fc, S23 albumen thermal stability.
Fig. 7 compares figure for Fc, S23 albumen resistance to aggregation.
Fig. 8 compares figure for protein molecular existence form in the experiment of Fc, S23 albumen resistance to aggregation.
Fig. 9 is the streaming figure after Fc, S23 albumen are combined with Fc receptors (Fc γ RI).
Specific embodiment
Below in conjunction with the drawings and specific embodiments, the present invention is described in further detail.Following embodiment is with this
Implemented under premised on inventive technique scheme, give detailed embodiment and specific operating process, but the present invention
Protection domain is not limited to following embodiments.
Embodiment 1：Expand Fc, S23 fragment gene
People source blood sample is taken, cell total rna, obtained cell are extracted with Trizol Reagent (Invitrogen companies)
Total serum IgE is dissolved in 50 water of the μ L without RNA enzyme.Then M-MLV Reverse Transcriptase kits (Promega companies) are used, using random
Primer, reverse transcription obtain cDNA.
According to the gene order (GenBank of the Fc of IgG:KJ905798.1), its amino acid sequence is analyzed, designs Fc genes
Forward and reverse primer amplification target fragment：Forward primer 5-GACGCGGCCCAGCC G GCCGCACCTGAA CTC
CTGGGGGGA C-3, (horizontal line is labeled as Sfi I restriction enzyme sites)；Reverse primer 5-GCCCTC C TCGAG TCA TTT ACC
CGG AGA CAG GGA G-3, (horizontal line is labeled as Xho I restriction enzyme sites).First with forward primer and reverse primer using cDNA as
Template carries out PCR, obtains Fc genetic fragments, recycles point mutation kit by four amino acid mutations of Fc segments into half Guang ammonia
Acid obtains S23 genetic fragments (gene order is Seq ID No.2, and amino acid sequence is Seq ID No.1).
Agarose gel electrophoresis recycles Fc, S23 genetic fragment, with Sfi I and Xho I digestion Fc, S23 genes and carrier
Fc, S23 gene are connect, Transformed E .coli Top10 competence, then by Psectag2A after glue recycling with carrier Psectag2A
Picking monoclonal send sequencing.According to sequencing result, the correct monoclonal of picking sequence is used for subsequent experimental.
Embodiment 2:It expresses and purifies Fc, S23
By each 40ug of Fc, S23 plasmid using PEI (2mg/mL PEI) (Polyethylenimine " Max ", (Mw 40,
000)-High Potency Linear PEI,Polysciences,Inc.,Catalog No.:24765-2,2g) transfect
293F cells, respectively with 293F expression culture medium (invitrogen) 40ml in 37 DEG C, 150rpm shaking table cultures 6 days.
Then, centrifuge (6000g, 4 DEG C, 15min) collecting 293F cell conditioned mediums, (supernatant is anti-using mouse anti-human igg Fc as first
The sheep anti-mouse igg that body, HRP are marked is that secondary antibody is to carry out protein immunoblot detection, and the results are shown in Figure 1, swimming lane 1：Marker；
Swimming lane 2：Fc cell conditioned mediums；Swimming lane 3：S23 cell conditioned mediums.The expression of clearly visible Fc, S23 albumen from figure), by the upper of collection
After clear filtering, Fc, S23 albumen are purified with Protein G fillers (GE companies).Then with the ultrafiltration that molecular cut off is 10kD from
The destination protein is concentrated by ultrafiltration in heart pipe (Merck Millipore companies), its purity is verified through SDS-PAGE, as a result such as Fig. 2 institutes
Show, swimming lane 2 is Fc segments, swimming lane 3 is S23 segments.
Embodiment 3：Fc, S23 existence form and molecular conformation
AKTA analyzes Fc, S23 existence form：By Fc, S23 protein concentration after purification to 1mg/ml, PBS (pH7.4) is
Elution buffer crosses 10/300 GL of Column Superdex 75Increase, wherein, flow velocity 0.5ml/min, so it is right
Its existence form is detected, and such as Fig. 3, reference standard curve is it can be found that the two molecular weight of albumen is about 56kDa, as a result
Show that they exist with dimeric forms.
CD detects protein molecular conformation：Fc, S23 albumen are diluted to 50ug/ml, PBS (pH7.4) is control, near purple
Its circular dichroism is detected under the conditions of outer end (wavelength X=190nm~260nm) different wave length, and then analyzes Protein secondary structure, is led to
10/300 GL of Column Superdex 75Increase (GE companies) are crossed to be analyzed, reference standard curve it can be found that
The two molecular weight of albumen is about 56kDa, and the results are shown in Figure 4, and there are one apparent troughs at λ=218nm, show above-mentioned egg
White secondary structure is beta sheet.
Embodiment 4：Fc, S23 stability are compared with resistance to aggregation
Denaturant conditions stability inferior is analyzed：Configuration concentration is the urea liquid of 0M to 10M, and concentration gradient 0.5M is common
21 samples；Then Fc, S23 albumen are added in ambient temperature overnight in the urea liquid of various concentration gradient handle, volume is
200ul, Fc, S23 final concentration of protein are 100ug/ml.Then, it is excited in 280nm with fluorescence detection equipment, is detected at 340nm
Each fluorescent intensity, as a result such as Fig. 5, it can be found that compared to Fc from figure, the fluorescence signal downward trend of S23 is slower,
Show that S23 more stablizes under denaturant conditions.
Thermal stability analysis：Compare Fc, S23 albumen (50ug/ml) thermal stability using circular dichroism spectrometer, PBS solution is
Blank control, set temperature gradient condition be per 2min increase 1 DEG C, terminate reaction temperature be 94 DEG C, per 30s wavelength X=
It is detected at 218nm and records data, as shown in fig. 6, analysis detects the molar absorptivity of its left and right circularly polarized light at different temperatures
The difference of coefficient, and then compare its thermal stability difference, it can be found that the thermal stability for modifying improved S23 is more much higher than Fc.
Resistance to aggregation is analyzed：
A) Fc, S23 final concentration of protein are adjusted to 2mg/ml, handle in 60 DEG C of water-baths, sample at regular intervals,
Absorbance is detected at λ=320nm and records data, wherein, PBS solution is blank control, compares the resistant to aggregation of Fc, S23 albumen
Property it is strong and weak, it can be found that S23 signals ascendant trend is relatively slow from Fig. 7, show that its resistant to aggregation ability is more preferable.
B) Fc, S23 protein sample that 60 degree of water-baths are handled to 551 hours pass through 13000rpm, and 4 DEG C, 15min is centrifuged,
Supernatant is taken to cross 75 Increase 10/300GL of Column Superdex, wherein, flow velocity 0.5ml/min, and then it is deposited
It is detected in form.As a result such as Fig. 8, analysis are found, two peaks of the apparent appearance of Fc albumen at this time, an aggregation peak, one two
Aggressiveness peak, and then only there are one uniform dimer peaks by S23, as existence form during firm expression and purification, illustrate that albumen does not have
Occur aggregation.
Embodiment 5：The combination of Flow cytometry Fc, S23 and Fc γ RI
U937 cell surfaces can express Fc γ RI, therefore compare Fc, S23 albumen and Fc γ RI parents with Flow cytometry experiments
And power.Fc, S23 albumen and U937 cells (U937 cell surfaces can express Fc γ RI) of gradient dilution are incubated 1 hour at 4 degree.
Unbonded albumen is washed off with culture medium.By the use of the goat anti-human igg Fc antibody (Sigma-Aldrich) of fluorescent marker as secondary antibody with
Cell is incubated 1 hour at 4 degree.It is cleaned with 1%PBSA and cell is resuspended, then sample is positioned on flow cytometer (Becton
Dickinson its binding force) is measured.Statistics indicate that, the S23 by modification transformation still keeps being combined work with Fc γ RI in Fig. 9
Property.
Sequence table
<110>Wuhan bancor Biotechnology Ltd.
<120>A kind of Fc segments of saltant type humanized IgG and preparation method and application
<130> 2017
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 217
<212> PRT
<213> S23
<400> 1
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Ser Phe Pro Pro Lys
1 5 10 15
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
20 25 30
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
35 40 45
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
50 55 60
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
65 70 75 80
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
85 90 95
Ala Leu Pro Ala Pro Ile Glu Ser Thr Ile Ser Lys Ala Lys Gly Gln
100 105 110
Ser Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
115 120 125
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
130 135 140
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
145 150 155 160
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
165 170 175
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
180 185 190
Phe Ser Cys Ser Val Met His Glu Ser Leu His Asn His Tyr Thr Gln
195 200 205
Lys Ser Leu Ser Leu Ser Pro Gly Lys
210 215
<210> 2
<211> 651
<212> DNA
<213> S23
<400> 2
gcacctgaac tcctgggggg accgtcagtc ttctgcttcc ccccaaaacc caaggacacc 60
ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 120
cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag 180
ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac 240
caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc 300
cccatcgagt gcaccatctc caaagccaaa gggcagtgcc gagaaccaca ggtgtacacc 360
ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa 420
ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 480
tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc 540
accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 600
tgtctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a 651
Claims (7)
1. a kind of Fc segments of saltant type humanized IgG, it is characterised in that：The Fc segments of the saltant type humanized IgG be by
It is obtained after introducing disulfide bond in the CH2 structural domains of the Fc segments of humanized IgG and CH3 structural domains.
2. the Fc segments of saltant type humanized IgG according to claim 1, it is characterised in that：The Fc of the saltant type humanized IgG
The amino acid of the 242nd, the 334th, the 343rd and the 431st is cysteine in the amino acid sequence of segment.
3. the Fc segments of saltant type humanized IgG according to claim 2, it is characterised in that：The Fc of the saltant type humanized IgG
The amino acid full length sequence of segment is Seq ID No.1.
4. the Fc segments of saltant type humanized IgG according to claim 3, it is characterised in that：The Fc of the saltant type humanized IgG
The coding gene sequence of segment is Seq ID No.2.
5. a kind of preparation method of the Fc segments of saltant type humanized IgG described in claim 2, its step are as follows：
(1) gene of the Fc segments of humanized IgG is obtained；
(2) design primer is amplified and is mutated by the designated amino acid base mutation in Fc into the base of encoding aminothiopropionic acid
Type Fc；
(3) carrier for expression of eukaryon is built with saltant type Fc gene orders, transfection mammalian cell carries out eukaryotic expression, purifying
Obtain target Fc segments.
6. application of the Fc segments of saltant type humanized IgG described in claim 1 in Fc fusion proteins are prepared.
7. application of the Fc segments of saltant type humanized IgG described in claim 1 in monoclonal antibody is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496466.5A CN108218998A (en) | 2017-12-31 | 2017-12-31 | A kind of Fc segments of saltant type humanized IgG and preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496466.5A CN108218998A (en) | 2017-12-31 | 2017-12-31 | A kind of Fc segments of saltant type humanized IgG and preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108218998A true CN108218998A (en) | 2018-06-29 |
Family
ID=62642374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711496466.5A Pending CN108218998A (en) | 2017-12-31 | 2017-12-31 | A kind of Fc segments of saltant type humanized IgG and preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108218998A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230077531A1 (en) * | 2021-05-27 | 2023-03-16 | Sanofi | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846874B2 (en) * | 2003-11-13 | 2014-09-30 | Hanmi Science Co., Ltd | IgG Fc fragment for a drug carrier and method for the preparation thereof |
| CN104788565A (en) * | 2003-05-02 | 2015-07-22 | 赞科股份有限公司 | Optimized Fc variants and methods for generation thereof |
| CN105949313A (en) * | 2011-03-29 | 2016-09-21 | 罗切格利卡特公司 | ANTIBODY Fc VARIANTS |
-
2017
- 2017-12-31 CN CN201711496466.5A patent/CN108218998A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104788565A (en) * | 2003-05-02 | 2015-07-22 | 赞科股份有限公司 | Optimized Fc variants and methods for generation thereof |
| US8846874B2 (en) * | 2003-11-13 | 2014-09-30 | Hanmi Science Co., Ltd | IgG Fc fragment for a drug carrier and method for the preparation thereof |
| CN105949313A (en) * | 2011-03-29 | 2016-09-21 | 罗切格利卡特公司 | ANTIBODY Fc VARIANTS |
Non-Patent Citations (2)
| Title |
|---|
| RUI GONG等: "Engineered Human Antibody Constant Domains with Increased Stability", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| XIAOBO CHEN等: "Optimization on Fc for Improvement of Stability and Aggregation Resistance", 《CURRENT PHARMACEUTICAL BIOTECHNOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230077531A1 (en) * | 2021-05-27 | 2023-03-16 | Sanofi | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
| US12297273B2 (en) * | 2021-05-27 | 2025-05-13 | Sanofi | Fc variant with enhanced affinity to Fc receptors and improved thermal stability |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111793129B (en) | An antibody or antigen-binding fragment thereof that specifically binds to a coronavirus | |
| CN106928371B (en) | Recombinant complement factor H-immunoglobulin fusion protein with complement regulation activity and preparation method and application thereof | |
| CN112175073B (en) | Neutralizing antibodies or antigen-binding fragments of coronaviruses | |
| CN110724198B (en) | Long acting fibronectin type III domain fusion proteins | |
| KR20140047038A (en) | Complement factor b analogs and their uses | |
| CN115038721B (en) | pH sensitive Fc variants | |
| CN107281475B (en) | Gene vaccine for preventing and treating tumor and preparation method and application thereof | |
| CN1944463B (en) | Fusion protein with alpha interferon activity and its coding gene and application | |
| CN105111315B (en) | MIP3 α-Fc fusion proteins and application thereof | |
| CN112010982A (en) | anti-GPC 3/CD3 bispecific antibody and application thereof | |
| JP2020529986A (en) | Cysteine-MAB conjugation method | |
| CN108218998A (en) | A kind of Fc segments of saltant type humanized IgG and preparation method and application | |
| CN113416244A (en) | Fully human novel crown IgG3 single-chain antibody and application thereof | |
| CN115400207A (en) | ACE2 modified protein and its application | |
| CN109666073B (en) | Anti-human DLL4 and anti-human VEGF bispecific antibody and preparation and application thereof | |
| CN114591988B (en) | Preparation method of genetically modified stem cells for activating tumor immunity | |
| CN114316060B (en) | Anti-human CD19 and CD206 bispecific antibody and its preparation method and application | |
| CN115667506A (en) | Recombinant ACE2-FC fusion molecules and methods of making and using the same | |
| KR101787485B1 (en) | Methods for producing recombinant PICP proteins and antibodies specifically binding thereto | |
| CN107936124A (en) | Fc fragment fusion proteins that TNFr strengthens with stability and resistance to aggregation and preparation method and application | |
| KR102048037B1 (en) | Multimeric Protein Display System using Cell Membrane Fluidity | |
| CN112778417B (en) | Isolated antigen BCMA-binding protein and use thereof | |
| CN115232207B (en) | Application of antibody-lysin (SM-ScFv-Fc-Ly) in the treatment of Streptococcus mutans infection | |
| CN101891817B (en) | Monoclonal antibody capable of preventing high mobility group box-1 (HMGB-1) and application thereof | |
| CN103773743A (en) | Recombinant uricase protein of rhesus and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180629 |
|
| RJ01 | Rejection of invention patent application after publication |